Patents by Inventor Jonathan A. Bard
Jonathan A. Bard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20030119096Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: December 3, 2001Publication date: June 26, 2003Inventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith
-
Publication number: 20030113771Abstract: This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.Type: ApplicationFiled: September 10, 2002Publication date: June 19, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Richard L. Weinshank, Carlos C. Forray
-
Publication number: 20030113772Abstract: This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.Type: ApplicationFiled: September 10, 2002Publication date: June 19, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Richard L. Weinshank, Carlos C. Forray
-
Publication number: 20030082641Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: January 26, 2001Publication date: May 1, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P.G. Gerald, Kenneth A. Jones
-
Publication number: 20030027254Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: December 3, 2001Publication date: February 6, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P.G. Gerald, Kenneth A. Jones
-
Publication number: 20020165380Abstract: This invention provides an isolated nucleic acid encoding a mammalian fb41a receptor, a purified mammalian fb41a receptor, vectors comprising isolated nucleic acid encoding a mammalian fb41a receptor, cells comprising such vectors, antibodies directed to a mammalian fb41a receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian fb41a receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian fb41a receptor, transgenic, nonhuman animals which express DNA encoding a normal or mutant mammalian fb41a receptor, methods of isolating a mammalian fb41a receptor, methods of treating an abnormality that is linked to the activity of the mammalian fb41a receptor, as well as methods of determining binding of compounds to mammalian fb41a receptors.Type: ApplicationFiled: August 9, 2001Publication date: November 7, 2002Inventor: Jonathan A. Bard
-
Patent number: 6448011Abstract: This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.Type: GrantFiled: October 16, 2000Date of Patent: September 10, 2002Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Richard L. Weinshank, Carlos C. Forray
-
Patent number: 6432655Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT4B receptor and an isolated nucleic acid molecule encoding a human 5-HT4B receptor, an isolated protein which is a mammalian 5-HT4B receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT4B receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT4B receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT4B receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT4B receptor, pharmaceutical compounds related to the human 5-HT4B receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with a human 5-HT4B receptor.Type: GrantFiled: June 14, 1999Date of Patent: August 13, 2002Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Theresa Branchek, Richard L. Weinshank
-
Publication number: 20020058267Abstract: Novel proteins which bind human &bgr;-amyloid peptide, polynucleotides which encode these proteins, and methods for producing these proteins are provided. Diagnostic, therapeutic, and screening methods employing the polynucleotides and polypeptides of the present invention are also provided. Transgenic animals and knockout animals are also provided.Type: ApplicationFiled: May 9, 2001Publication date: May 16, 2002Applicant: American Home Products CorporationInventors: Bradley A. Ozenberger, Jonathan A. Bard, Eileen M. Kajkowski, Jack S. Jacobsen, Stephen G. Walker, Heidi Sofia, David Howland
-
Publication number: 20020055459Abstract: This invention is directed to the three dimensional crystal structure of Beta-site APP Cleaving Enzyme (BACE), and to the use of this structure in rational drug design methods to identify agents that may interact with active sites of BACE. Such agents may represent new therapeutics in the treatment and/or prevention of Alzheimer's Disease.Type: ApplicationFiled: September 19, 2001Publication date: May 9, 2002Inventors: Rajiv Chopra, Kristine Svenson, Bethany Annis, Tatos N. Akopian, Jonathan Bard, Mark Lloyd Stahl, William S. Somers
-
Patent number: 6376243Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT4B receptor and an isolated nucleic acid molecule encoding a human 5-HT4B receptor, an isolated protein which is a mammalian 5-HT4B receptor, an isolated protein which is a human 5-HT4B receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT4B receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT4B receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT4B receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT4B receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT4B receptor, pharmaceutical compounds related to the human 5-HT4B receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human 5-HT4B receptor.Type: GrantFiled: November 29, 1999Date of Patent: April 23, 2002Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Theresa Branchek, Richard L. Weinshank
-
Patent number: 6368812Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: April 9, 1998Date of Patent: April 9, 2002Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P. G. Gerald, Kenneth A. Jones
-
Patent number: 6329197Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: July 23, 1997Date of Patent: December 11, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith
-
Patent number: 6300087Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT4B receptor and an isolated nucleic acid molecule encoding a human 5-HT4B receptor, an isolated protein which is mammalian 5-HT4B receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT4B receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT4B receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT4B receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT4B receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT4B receptor, pharmaceutical compounds related to the human 5-HT4B receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with a human 5-HT4B receptor.Type: GrantFiled: November 29, 1999Date of Patent: October 9, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Theresa Branchek, Richard L. Weinshank
-
Patent number: 6287788Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: November 25, 1998Date of Patent: September 11, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P. G. Gerald, Kenneth A. Jones
-
Publication number: 20010009766Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: July 23, 1997Publication date: July 26, 2001Inventors: JONATHAN A. BARD, BETH BOROWSKY, KELLI E. SMITH
-
Patent number: 6210967Abstract: This invention provides an isolated nucleic acid encoding a mammalian LPA receptor, a purified mammalian LPA receptor, vectors comprising isolated nucleic acid encoding an mammalian LPA receptor, cells comprising such vectors, antibodies directed to a mammalian LPA receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian LPA receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian LPA receptor, transgenic, nonhuman animals which express DNA encoding a normal or a mutant mammalian LPA receptor, methods of isolating an mammalian LPA receptor, methods of treating an abnormality that is linked to the activity of the mammalian LPA receptor, as well as methods of determining binding of compounds to mammalian LPA receptors.Type: GrantFiled: December 10, 1997Date of Patent: April 3, 2001Assignee: Synaptic Pharmaceutical CorporationInventor: Jonathan A. Bard
-
Patent number: 6156518Abstract: This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.Type: GrantFiled: December 29, 1999Date of Patent: December 5, 2000Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Richard L. Weinshank, Carlos C. Forray
-
Patent number: 6083749Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4B receptor and an isolated nucleic acid molecule encoding a human 5-HT.sub.4B receptor, an isolated protein which is a mammalian 5-HT.sub.4B receptor, an isolated protein which is a human 5-HT.sub.4B receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4B receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.4B receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT.sub.4B receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT.sub.4B receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT.sub.4B receptor, pharmaceutical compounds related to the human 5-HT.sub.4B receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human 5-HT.sub.4B receptor.Type: GrantFiled: July 27, 1994Date of Patent: July 4, 2000Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Theresa Branchek, Richard L Weinshank
-
Patent number: 5985585Abstract: The invention provides for processes for identifying chemical compounds which specifically bind to a human 5-HT.sub.4B having the amino acid sequence of SEQ ID NO: 2.Type: GrantFiled: June 15, 1995Date of Patent: November 16, 1999Assignee: Synaptic Pharmaceutical CoorporationInventors: Jonathan A. Bard, Theresa Branchek, Richard L. Weinshank